Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PYGL | P06737 | 3/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.35 |
| ▸ | RELA | Q04206 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14015808 | 0.84 | EPHX2 (0.41) | EPHX2ATMDRD2KDM1AMAOB | |
| SCHEMBL13299034 | 0.84 | EPHX2 (0.47) | EPHX2ATMDRD2KDM1AMAOB | |
| SCHEMBL13299015 | 0.84 | EPHX2 (0.47) | EPHX2ATMDRD2KDM1AMAOB | |
| SCHEMBL14015843 | 0.82 | EPHX2 (0.40) | EPHX2ATMDRD2KDM1AMAOB | |
| SCHEMBL3328981 | 0.82 | PYGL (0.49) | EPHX2ATMDRD2KDM1AMAOB | |
| SCHEMBL13299051 | 0.81 | EPHX2 (0.44) | EPHX2ATMDRD2KDM1AMAOB | |
| SCHEMBL8652209 | 0.81 | KMT2A (0.46) | EPHX2ATMDRD2KDM1AMAOB | |
| SCHEMBL7329129 | 0.81 | KMT2A (0.46) | EPHX2ATMDRD2KDM1AMAOB | |
| SCHEMBL3332302 | 0.81 | EPHX2 (0.42) | EPHX2ATMDRD2KDM1AMAOB | |
| SCHEMBL13299032 | 0.81 | EPHX2 (0.42) | EPHX2ATMDRD2KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658067-B1 | INDOLAMIDE DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2008-11-12 | — | — | EP | disclosed |
| US-20080064691-A1 | Heterocyclic Amide Derivatives Which Possess Glycogen Phosphorylase Inhibitory Activity | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064691-A1 | Heterocyclic Amide Derivatives Which Possess Glycogen Phosphorylase Inhibitory Activity | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064691-A1 | Heterocyclic Amide Derivatives Which Possess Glycogen Phosphorylase Inhibitory Activity | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20060211760-A1 | Indolamide derivatives which possess glycogen phosphorylase inhibitory activity | ASTRAZENECA AB (SE) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211760-A1 | Indolamide derivatives which possess glycogen phosphorylase inhibitory activity | PYGL, PYGM, PYGB | EPHX2 2943/4885ATM 2821/4885DRD2 2419/4885 |
| US-20080064691-A1 | Heterocyclic Amide Derivatives Which Possess Glycogen Phosphorylase Inhibitory Activity | PYGL, PYGM, GYS1 | EPHX2 2085/4885ATM 4326/4885DRD2 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.